Eloralintide
Lilly's selective amylin agonist, which reached 20% weight loss at 48 weeks in Phase 2. Approved nowhere yet.
Also listed as LY3841136.
Peptide Compare tracked 5 vendors selling Eloralintide on 20 Sep 2026. The cheapest in-stock 10 mg vial is $6.58 per mg at Peptides Collective after its 30% coupon, 34% under the $9.95 median. Prices are scraped from vendor sites; trust scores come from Finnrick blind tests.
Some outbound links may earn us a commission. Vendors cannot pay to improve rankings.
Best value right now · 10 mg
Peptides Collective
IN STOCKUNTESTED
Per mg34% under the $9.95 median
Vial price10 mg · verified Sep 20
Avg per mg · 10 mg
$12.30−38.2%
Ranged $12.30 – $31.43 across 5 vendorsCompare 4 vendors · 10 mg
Across all sizes, verified in-stock listings run $75.00 to $199.00 from 5 vendors.
VendorStock
Eloralintide prices verified Sep 20, 2026
$6.58/mgPeptides Collective · $65.80
Buy best priceSee how Eloralintide moved against the rest of the catalogue in the Peptide Price Index: median price per mg now versus 30 and 90 days ago, every tracked peptide, with a CSV.
Eloralintide price by vial size
| Vial size | Lowest per mg | Vial price | Vendor |
|---|---|---|---|
| 1 mg | $89.99 | $89.99 | Umbrella Labs1 vendor carries it |
| 5 mg | none verified in stock | 1 vendor carries it | |
| 10 mg | $6.58 | $65.80 | Peptides Collective4 vendors carry it |
Verified 20 Sep 2026. Lowest figures are in-stock listings checked within the last week, with any coupon applied; a size with none says so.
Price movement · 30 days
−73.1%median per mg, all sizes
Cheapest ever recorded: $7.50/mg on Sep 15. Today matches it.See our top-ranked Eloralintide vendors
Ranked by Finnrick trust score, independent lab testing, and price.
Compare Eloralintide head-to-head
- Eloralintide vs Retatrutide
- Eloralintide vs Tirzepatide
- Eloralintide vs Semaglutide
- Eloralintide vs Cagrilintide
- Eloralintide vs AOD-9604
- Eloralintide vs 5-Amino-1MQ
Quick Summary
A once-weekly, selective amylin receptor agonist from Eli Lilly (LY3841136), designed to act at the amylin receptor without the calcitonin receptor. It completed Phase 2 in 2025 and is approved nowhere. Available from 5 vendors, priced from $75.00 to $435.00.
Research: In a 48-week Phase 2 trial of 263 adults with obesity or overweight and no diabetes (Billings et al, Lancet 2025;406(10520):2631-2643, PMID 41207310; NCT06230523), mean weight change on the efficacy estimand was -9% at 1 mg, -12% at 3 mg, -18% at 6 mg, -20% at 9 mg, -20% with 6 to 9 mg escalation and -16% with 3 to 9 mg escalation, against -0.4% on placebo. The trial ran at 46 US centres and Lilly funded it.
Side effects: From Billings 2025: nausea in 11% to 64% of the eloralintide arms (64% at 6 mg) against 14% on placebo, fatigue in 0% to 46% (46% with 6 to 9 mg escalation) against 12% on placebo
Phase 2Eli Lilly. Phase 2 completed 14 August 2025. No regulator has approved it and Drugs@FDA holds no record for it.
- 5 of 5 vendors currently have it in stock
- Most common vial size: 10mg
- Category: Weight Loss (GLP-1) — GLP-1 receptor agonists for weight management
Get Eloralintide price alerts
Join the list — price-drop alerts for this peptide are in the works and you'll be first on them.